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Mechanical Rescue
of the Heart in Shock*
José A. Tallaj, MD,†‡ Martı´n Cadeiras, MD†
Birmingham, Alabama
Cardiogenic shock (CS) is a state of extreme hypoperfusion
owing to pump failure manifested by altered mental status,
cool extremities, and/or renal failure. This hypoperfusion
leads to release of catecholamines and other inflammatory
mediators, which further perpetuates myocardial ischemia
and injury, resulting in additional impairment in systemic
and tissue perfusion. Any cause of acute severe cardiac
failure may lead to CS.
See page 688
Treatment of CS largely relies on anecdotal experience
and a few small clinical studies. This group of patients
constitutes a population with an extremely high mortality
that requires a rapid and systematic response. For these
reasons, randomized trials have been challenging, and the
clinical decision-making algorithm is subject to continuing
debate and consensus processes. The therapy consists of
rapidly restoring cardiac output and peripheral perfusion by
the use of inotropic agents and vasopressors. Intra-aortic
balloon counterpulsation (IABP) has long been the main-
stay of mechanical therapy for acute CS that fails initial
stabilization with medical therapy. Placement of IABP
improves coronary and peripheral perfusion by improving
left ventricular (LV) performance and by acutely decreasing
afterload. However, IABP does not artificially augment
cardiac output and therefore may not work in patients with
more advanced disease. There are no randomized trials
evaluating the effect on IABP alone in CS. In the SHOCK
(Should We Emergently Revascularize Occluded Coronar-
ies for Cardiogenic Shock?) trial, IABP therapy resulted in
a significantly lower mortality rate in patients with acute
myocardial infarction (MI), especially in those who had
received concomitant thrombolytic treatment (1). In the
large National Registry of Myocardial Infarction, use of
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with high IABP use, irrespective of revascularization status
(2). A recent meta-analysis of cohort studies in the setting
of ST-segment elevation MI complicated by CS supported
the benefit of IABP therapy only in patients who received
thrombolysis but not in those who underwent primary
percutaneous coronary intervention (3). Despite these con-
troversial results, support with pressors and inotropic agents,
IABP, and early revascularization is the current standard of
care in patients presenting with CS. However, once shock
develops, the mortality rate remains higher than 50% with
one-half of the deaths occurring within the first 48 h (4).
iven this high mortality, it is increasingly recognized that
mechanical device that is quick to implant, easy to care for
ith minimal complications, and able to rapidly restore
dequate circulatory support could significantly improve the
rognosis of patients presenting with severe CS. Percuta-
eously implanted devices are particularly appealing in this
ituation. Percutaneous left ventricular assist devices
pVADs) can interrupt the cycle of ischemia, hypoperfu-
ion, and myocardial depression by providing adequate
upport and perfusion while allowing the medical team to
erform high-risk percutaneous or surgical revasculariza-
ion, bridge to recovery of LV function, or transition to
ore definitive support. Several pVADs are currently avail-
ble. The TandemHeart pVAD (CardiacAssist, Inc., Pitts-
urgh, Pennsylvania) removes blood from the left atrium
hrough a femoral vein cannula placed transseptally. Blood
s then returned to the arterial circulation through a cannula
laced in the femoral artery. Another pVAD in clinical use
s the Impella 2.5 (Abiomed Inc., Danvers, Massachusetts),
hich is placed across the aortic valve. Extracorporeal
embrane oxygenation, which involves circulation through
n oxygenator mitigating the work of the pulmonary and
ystemic circulation, has also been used in patients with CS.
In this issue of the Journal, Kar et al. (5) describe a single
enter’s experience using the TandemHeart pVAD as a
alvage therapy for patients in severe refractory CS. We
ant to emphasize “refractory” CS because the patients
ncluded in the study were failing what is considered
tandard therapy for CS with pressors and IABP. In
ddition, 48% of the patients were actively receiving cardio-
ulmonary resuscitation (CPR) during implantation. The
ohort of 117 consecutive patients is not only the largest but
lso the sickest collection of patients with refractory CS in
ublished reports. Interestingly, 32% of the patients had
onischemic cardiomyopathy, with only 32% of those with
n acute cause of heart failure such as myocarditis or allograft
ejection. An impressive 60% of the patients were alive at 30
ays, with 55% surviving 6 months and a slightly better
utcome in patients with nonischemic cardiomyopathy.
The TandemHeart seems to be the ideal device for such
ituations. Quick to implant? It took an average of 15 to 65
in to implant the TandemHeart, with shorter times uponrowing experience with the device. Easy to care for with
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support was 5.8  4.8 days, with a considerably low
omplication rate. In addition to the expected bleeding
omplications, sepsis and systemic inflammatory response
yndrome were seen in 30% of the patients, likely because of
mplantation under suboptimal conditions and while pa-
ients were undergoing CPR. Able to rapidly restore adequate
irculatory support? The hemodynamic profile and biochem-
cal markers of shock and low output state improved rapidly
fter implant. Mean cardiac index increased from 0.5  0.8
/min/m2 to 3.0  0.9 l/min/m2 with support. These
beneficial changes were already apparent in the first hour
after institution of support.
The idea that a mechanical support device can be useful
in patients with CS is not new. It was initially described in
CS associated with acute MI (6). Several small randomized
trials using the TandemHeart (7,8) or Impella (9) device in
comparison with IABP in patients with CS have been
published. A recent meta-analysis combining these 3 trials
(10) included 100 patients, with 53 of those receiving a
pVAD. Interestingly, the improvement in early hemody-
namics in patients treated with pVAD was not associated
with an improvement in survival. It is important to note that
the patients included in the current study were refractory to
vasopressors and IABP or were getting CPR at the time of
implantation; therefore, the expected mortality rate in
this population would likely be higher than the mortality
rates seen in these earlier randomized trials that included
patients in less critical condition. In addition, some
investigators have shown the feasibility of surgically
implanted devices in patients with acute post-MI CS
(11), but these devices are more expensive and take longer
to implant and recover after surgery. Therefore, pVADs, in
particular the TandemHeart, would be ideal for patients in
severe or refractory CS. One of the characteristics that
stands out in the TandemHeart as opposed to other pVADs
that is important in this population is the possibility of
providing up to 5 l/min of assisted output.
Several questions remain about the potential widespread
use of these technologies, especially given the cost associated
with these devices. How can we apply the results of this
study to the “real world?” Who would benefit the most from
these advances in technology? When and who would decide
if these technologies are being applied in a timely manner,
before implantation is futile? There is a spectrum of severity
in patients with CS. Those requiring CPR represent the
group of patients with the worst possible outcome, as
evidenced in the current study. But even in the group who
received CPR, a remarkable 43% were alive at 30 days,
illustrating the difficulty in using a single clinical parameter
in deciding to continue therapy versus considering therapy
futile. Another important parameter that was not assessed in
the current study, albeit difficult to assess in the emergent
situation, is right ventricular function, either by imaging or
hemodynamic criteria. Right ventricular dysfunction is an
independent predictor of survival in post-MI patients (12).Similarly, right ventricular dysfunction that occurs in sur-
gically implanted LV assist device is associated with end-
organ failure and a high mortality rate (13). These 2
parameters illustrate the difficulty of evaluating an individual
patient in such a critical state and predicting clinical
outcome.
While we wait for additional studies or new guidelines,
there are some considerations that may help improve out-
comes while decreasing costs and unnecessary procedures in
patients with CS. Set early goals of therapy aimed at prompt
recognition of CS, correction of modifiable factors, and
establishment of optimal end-organ perfusion. The goals
proposed by Kar et al. (5), a mixed venous saturation 70%
and mean arterial pressure 60 mm Hg, are indicative of
adequate perfusion. An escalating approach to therapy like
the one used in the current study seems reasonable, starting
with pressors and IABP before “escalating” to a pVAD
unless the patients is in extremis requiring CPR. Determine
targets of therapy early in the course of treatment, like
revascularization, bridge to recovery, or transition to more
permanent support such as transplantation or surgically
implanted LV assist device. Finally, it is important to define
futility and discuss end-of-life issues with patients and their
families. It is important to keep in mind that this type of
technology can prolong dying, as opposed to alleviating
suffering or improving survival. A multidisciplinary ap-
proach to the group of patients not improving despite
maximal efforts should also include social workers and
palliative care personnel.
In conclusion, Kar et al. (5) have demonstrated that
escalating therapy that includes implantation of a Tandem-
Heart pVAD in patients with refractory CS is safe and
efficacious. Although we are cautiously optimistic about the
potential of mechanical rescue of the heart in shock,
additional studies are needed to answer the questions raised
from the current study: how to apply this expensive tech-
nology in the “real world” and how to define when ongoing
efforts are futile. In the meantime, the responsibility of the
scientific community is to strive to develop a multidisci-
plinary, systematic approach to gravely ill patients who
might benefit from mechanical circulatory support therapy
to ensure the best possible outcome.
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